First antibody-drug conjugate facility to receive three provincial regulatory approvals for segmented manufacturing.
New perfusion technologies and AI-driven controls are accelerating adoption across commercial biologics manufacturing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results